- Birte Twisselmann, technical editor
- BMJ
A webchat on the benefits and harms issue took place on 8 July 2004.1 The editors of the theme issue began by raising several topics for discussion.
Should complementary and alternative medicine have featured as much as other aspects? Would their recognition improve evidence about their benefits and harms?
How will the European Trials Directive affect trials focusing on the safety of treatments?
Has anyone tried to report adverse effects in a developing country?
What is the role of consumers (patients) in determining an acceptable ratio of benefit to harm?
Should vulnerable populations in whom drugs are not licensed such as pregnant women, children, and elderly people be considered?
The topic that dominated the …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Ethical considerations
Published 14 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 14 February 2012
Re: Raised inflammatory markers
Published 14 February 2012
Re: Physical activity for cancer survivors: meta-analysis of randomised controlled trials
Published 14 February 2012
Smokefree cars in Wales: Laws are better
Published 14 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012